C5 — patent landscape · Sugi Predict

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4985669	0.52	2/20
Bromide (SCHEMBL5457346)	0.51	2/20
SCHEMBL5661493	0.49	2/20
SCHEMBL1545595	0.49	2/20
SCHEMBL1545758	0.48	2/20
SCHEMBL4237939	0.44	2/20
SCHEMBL4229305	0.44	2/20
SCHEMBL4236451	0.43	2/20
SCHEMBL3313965	0.42	2/20
SCHEMBL4236386	0.42	2/20
SCHEMBL3186250	0.41	2/20
SCHEMBL4236662	0.40	2/20
SCHEMBL4226948	0.40	2/20
SCHEMBL4238811	0.40	2/20
SCHEMBL4660367	0.38	2/20
SCHEMBL4660370	0.38	2/20
SCHEMBL2306206	0.35	2/20
Oxaprozin (SCHEMBL3286)	1.00	1/20
Carprofen (SCHEMBL3909)	1.00	1/20
Carprofen (SCHEMBL3910)	1.00	1/20

Clinical trials — most relevant to C5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS	PHASE4	COMPLETED
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation	PHASE3	COMPLETED
A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC GENERIUM, Russian Federation)	PHASE3	COMPLETED
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN	PHASE3	RECRUITING
The Effect of Some Drugs Used in Treatment of Vasculitis on the Complement System in Children	PHASE3	UNKNOWN
Ravulizumab and COVID-19	PHASE3	UNKNOWN
Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD	PHASE3	ACTIVE_NOT_RECRUITING
Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576	PHASE3	COMPLETED
Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis	PHASE2	COMPLETED
Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab	PHASE2	WITHDRAWN
Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder	PHASE2	WITHDRAWN
Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder	PHASE2	ACTIVE_NOT_RECRUITING
Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury	PHASE2	COMPLETED
Complement C5 mAb in the Treatment of Anti-GBM Disease	PHASE2	COMPLETED
Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy	PHASE1	COMPLETED
Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects	PHASE1	COMPLETED
TP10 Use in Patients With C3 Glomerulopathy (C3G)	PHASE1	WITHDRAWN
Complement C5a Receptors in Hidradenitis Suppurativa	nan	COMPLETED
Effect of Platelet Storage on Complement Activation	nan	UNKNOWN
A Real-world, Multi-center, Prospective, Observational Study for PNH in China	nan	COMPLETED
Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome	nan	COMPLETED
The Pharmacokinetics and Pharmacodynamics of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria	nan	COMPLETED
Complement Activation in the Lysosomal Storage Disorders	nan	WITHDRAWN
Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in Systemic Lupus Erythematosus (DYSALARM-322)	nan	RECRUITING
Transcriptome and Metabolic Analyses of CHAPLE Disease	nan	UNKNOWN
Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria®	nan	COMPLETED
DKK-3 rs11544814 and CFH rs10737680 Polymorphism and Protein Levels With Non Surgical Periodontal Therapy in Periodontitis Patients With and Without CAD	nan	UNKNOWN
VOCs in Kidney and Liver Transplants	nan	UNKNOWN
Role of Renal Artery Doppler in Critically Ill Children With Acute Kidney Injury	nan	UNKNOWN
Hematological Response in Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Anti-C5 Antibody: an External Control Arm Study for Iptacopan Use in Anti-C5 naïve Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a C5 binder may also engage these)

Protein	Name	Similarity
P06684	—	1.000	P06684 →
I2C090	—	1.000	I2C090 →
P08650	—	1.000	P08650 →
Q0ZZJ6	—	1.000	Q0ZZJ6 →
Q91132	—	0.997	Q91132 →
P98093	—	0.993	P98093 →
J3S836	—	0.992	J3S836 →
Q01833	—	0.992	Q01833 →
P01027	—	0.991	P01027 →
Q3UU35	—	0.987	Q3UU35 →
A0RZC6	—	0.987	A0RZC6 →
P12387	—	0.987	P12387 →
P01029	—	0.987	P01029 →
A0AAQ4VMX2	—	0.986	A0AAQ4VMX2 →
P20740	—	0.985	P20740 →
P01030	—	0.985	P01030 →
P08649	—	0.984	P08649 →
P28665	—	0.984	P28665 →
Q6YHK3	—	0.983	Q6YHK3 →
C9XI66	—	0.983	C9XI66 →
P0C0L4	—	0.982	P0C0L4 →
P0C0L5	—	0.982	P0C0L5 →
Q63041	—	0.982	Q63041 →
P01025	—	0.981	P01025 →
P01026	—	0.981	P01026 →
Q91687	—	0.981	Q91687 →
P01024	—	0.981	P01024 →
P28666	—	0.981	P28666 →
Q8R422	—	0.980	Q8R422 →
Q03626	—	0.980	Q03626 →